Oncodesign collaborates with InterSystems to accelerate Drug Discovery in Oncology
Oncodesign collaborates with InterSystems to accelerate Drug Discovery in Oncology
Today’s oncology
discovery involves the concept of personalized medicine to oncological research
and engagement of specialists form their fields to gain insights into
pharmacology.
On May 18,2021, InterSystems, a leading data management company in healthcare, financial and logistics sectors has announced a new long-term partnership with Oncodesign, a biotechnology and biopharmaceutical company based in Paris, France. This collaboration will involve Oncosign adapt InterSystems’ solutions to utilize and organize health data to catalyze their medical search for advanced treatments and discovery of drug formulations in Oncology using Artificial Intelligence (AI).
Oncosnipe®,
Oncodesign’s patented platform to identify and validate new therapeutic targets
will integrate with InterSystems IRIS for Health™ under this
collaboration.
The process would
involve Oncodesign establish an AI business unit to store and manage clinical
and pre-clinical data collected from pharmaceutical research processes that
focuses on optimizing the development of Oncosnipe® system and its appropriate
functioning of algorithms. Further, Electroconvulsive therapy (ECT) analyzes
and makes use of the consolidated data provided by InterSystems IRIS for
Health™ data platform and Oncodesigns’ AI business unit and optimizes the
development of Oncosnipe® through easier operation of its algorithms.
This partnership will
bring experts from the field of data science, pharmacology, biology, chemistry,
clinical research and artificial intelligence to work together for advancements
of drug discovery in Oncology. InterSystems’ goal is to equip Oncodesign and
build advanced and intelligent architectures for oncological research. Undoubtedly,
we can expect extraordinary outcomes as the power of data, AI and oncological
treatment combine.
Comments
Post a Comment